Over the years, the difficulties of translating fundamental biomarker discoveries to diagnostic clinical applications have caused a lot of frustration to researchers and clinicians, in both academia and industry. It is a lengthy and costly process. One of the reasons for this barrier is the lack of understanding of individual stakeholders on the phases and associated constrains that need to be achieved and solved to be successful. These include a proper intend of use, discovery tools, sample collection, data collection, data analysis, assay development, assay validation, clinical performance, regulatory approval, and market access evaluation before a diagnostic test can be commercialized and used clinically.
Studies aiming to tackle and favor the acceleration of the discovery, development and validation of biomarkers and associated assays are needed. These will ultimately aid for the earliest possible diagnosis, stratification, prognosis and monitoring of neurological diseases.
Submissions are welcome for the following article types: original research, review, mini-reviews, systematic reviews, research protocol, opinion and hypothesis. We particularly welcome contributions that include, but are not limited to, the following topics:
1) Acceleration of discovery of biomarkers
2) Novel insights on the development of biomarkers assays
3) Effective methods of validation of new biomarkers and associated assays
Over the years, the difficulties of translating fundamental biomarker discoveries to diagnostic clinical applications have caused a lot of frustration to researchers and clinicians, in both academia and industry. It is a lengthy and costly process. One of the reasons for this barrier is the lack of understanding of individual stakeholders on the phases and associated constrains that need to be achieved and solved to be successful. These include a proper intend of use, discovery tools, sample collection, data collection, data analysis, assay development, assay validation, clinical performance, regulatory approval, and market access evaluation before a diagnostic test can be commercialized and used clinically.
Studies aiming to tackle and favor the acceleration of the discovery, development and validation of biomarkers and associated assays are needed. These will ultimately aid for the earliest possible diagnosis, stratification, prognosis and monitoring of neurological diseases.
Submissions are welcome for the following article types: original research, review, mini-reviews, systematic reviews, research protocol, opinion and hypothesis. We particularly welcome contributions that include, but are not limited to, the following topics:
1) Acceleration of discovery of biomarkers
2) Novel insights on the development of biomarkers assays
3) Effective methods of validation of new biomarkers and associated assays
